Global Microarray-based Non-Invasive Prenatal Testing Market Growth (Status and Outlook) 2024-2030

Global Microarray-based Non-Invasive Prenatal Testing Market Growth (Status and Outlook) 2024-2030

For expectant mothers, microarray-based non-invasive prenatal testing (NIPT) provides a secure and educational screening choice. To determine the likelihood of chromosomal abnormalities in the foetus, it examines cell-free foetal DNA that is circulating in the mother's blood. In contrast to conventional techniques that may result in miscarriage, NIPT is a blood test. With a detection rate for Down syndrome that is above 99%, this extremely reliable test yields findings in less than a week. In comparison to earlier techniques, it can even test for a wider spectrum of disorders. However, NIPT is only a screening tool and not a conclusive diagnosis. It could require more testing to be confirmed. It might not be appropriate for all pregnancies, and the cost and insurance coverage can differ.

The global Microarray-based Non-Invasive Prenatal Testing market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Microarray-based Non-Invasive Prenatal Testing Industry Forecast” looks at past sales and reviews total world Microarray-based Non-Invasive Prenatal Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Microarray-based Non-Invasive Prenatal Testing sales for 2023 through 2029. With Microarray-based Non-Invasive Prenatal Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Microarray-based Non-Invasive Prenatal Testing industry.

This Insight Report provides a comprehensive analysis of the global Microarray-based Non-Invasive Prenatal Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Microarray-based Non-Invasive Prenatal Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Microarray-based Non-Invasive Prenatal Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microarray-based Non-Invasive Prenatal Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Microarray-based Non-Invasive Prenatal Testing.

United States market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Microarray-based Non-Invasive Prenatal Testing players cover Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Microarray-based Non-Invasive Prenatal Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:
Trisomy Detection
Microdeletion Syndromes
Other

Segmentation by Application:
Hospitals & Clinics
Independent Laboratories

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Trisomy Detection
Microdeletion Syndromes
Other

Segmentation by Application:
Hospitals & Clinics
Independent Laboratories

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Ariosa Diagnostics (Roche)
BGI Group
Eurofins LifeCodexx GmbH
Illumina
Laboratory Corporation of America
Myriad Genetics
Natera
PerkinElmer Inc
Quest Diagnostics
Sequenom

Please note: The report will take approximately 2 business days to prepare and deliver.